Equities analysts expect that Endocyte, Inc. (NASDAQ:ECYT) will post earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Endocyte’s earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.27). Endocyte also reported earnings of ($0.25) per share in the same quarter last year. The firm is scheduled to report its next earnings results on Thursday, August 3rd.
According to Zacks, analysts expect that Endocyte will report full year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.93) to ($0.84). For the next year, analysts anticipate that the company will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.76) to ($0.73). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Endocyte.
Endocyte (NASDAQ:ECYT) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.01. Endocyte had a negative return on equity of 29.67% and a negative net margin of 59,808.57%. The company had revenue of $0.01 million during the quarter. During the same period in the prior year, the business posted ($0.24) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year.
ECYT has been the topic of several recent analyst reports. Cowen and Company reaffirmed a “buy” rating on shares of Endocyte in a report on Wednesday, April 5th. Wedbush cut Endocyte from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Monday, June 5th. Zacks Investment Research raised Endocyte from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Thursday, June 8th. Finally, ValuEngine cut Endocyte from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $3.58.
ILLEGAL ACTIVITY WARNING: “Analysts Expect Endocyte, Inc. (ECYT) to Post -$0.25 Earnings Per Share” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/08/06/analysts-expect-endocyte-inc-ecyt-to-post-0-25-earnings-per-share-updated.html.
Institutional investors have recently made changes to their positions in the stock. Spark Investment Management LLC purchased a new position in shares of Endocyte during the second quarter worth $177,000. Renaissance Technologies LLC boosted its position in shares of Endocyte by 284.4% in the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares in the last quarter. RMB Capital Management LLC boosted its position in shares of Endocyte by 8.8% in the first quarter. RMB Capital Management LLC now owns 264,885 shares of the biopharmaceutical company’s stock worth $681,000 after buying an additional 21,500 shares in the last quarter. FMR LLC boosted its position in shares of Endocyte by 0.7% in the first quarter. FMR LLC now owns 3,509,035 shares of the biopharmaceutical company’s stock worth $9,018,000 after buying an additional 24,625 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of Endocyte by 3.9% in the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,711 shares in the last quarter. 33.02% of the stock is currently owned by institutional investors.
Endocyte (NASDAQ ECYT) traded down 2.72% during midday trading on Monday, hitting $1.43. The stock had a trading volume of 401,349 shares. The company has a 50-day moving average price of $1.50 and a 200-day moving average price of $2.12. Endocyte has a 52 week low of $1.36 and a 52 week high of $3.49. The stock’s market cap is $60.73 million.
Endocyte Company Profile
Get a free copy of the Zacks research report on Endocyte (ECYT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
